Oxford Gene Technology, Oxford, UK, has expanded its Cytocell Aquarius line of fluorescence in situ hybridization (FISH) probes for pathology, with the introduction of three new probes: FUS Breakapart and FOXO1 Breakapart, both carrying the CE mark, and TFE3 Breakapart, for research use only. The genes for FUS and FOXO1 are both implicated in several debilitating neoplastic diseases. Recurrent rearrangements involving the FUS gene with a number of different partner genes have been reported in various types of neoplastic disease, notably soft tissue sarcomas and acute myeloid leukemia. Translocations involving the FOXO1 gene are associated with approximately 80% of cases of alveolar rhabdomyosarcoma. To minimize the risk of experimental errors, probes are supplied as ready-to-use, premixed solutions. For more information, visit Oxford Gene Technology.